MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two
Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two